Berg Kasper D, Thomsen Frederik B, Nerstrøm Camilla, Røder Martin A, Iversen Peter, Toft Birgitte G, Vainer Ben, Brasso Klaus
Department of Urology, Copenhagen Prostate Cancer Center, University of Copenhagen, Copenhagen, Denmark.
Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
BJU Int. 2016 Jun;117(6):883-9. doi: 10.1111/bju.13439. Epub 2016 Feb 22.
To investigate whether the International Society of Urological Pathology (ISUP) 2005 revision of the Gleason grading system has influenced the risk of biochemical recurrence (BCR) after radical prostatectomy (RP), as the new guideline implies that some prostate cancers previously graded as Gleason score 6 (3 + 3) are now considered as 7 (3 + 4).
A matched-pair analysis was conducted. In all, 215 patients with Gleason score 6 or 7 (3 + 4) prostate cancer on biopsy who underwent RP before 31 December 2005 (pre-ISUP group), were matched 1:1 by biopsy Gleason score, clinical tumour category, PSA level, and margin status to patients undergoing RP between 1 January 2008 and 31 December 2011 (post-ISUP group). Patients were followed until BCR defined as a PSA level of ≥0.2 ng/mL. Risk of BCR was analysed in a competing-risk model.
The median follow-up was 9.5 years in the pre-ISUP group and 4.8 years in the post-ISUP group. The 5-year cumulative incidences of BCR were 34.0% and 13.9% in the pre-ISUP and post-ISUP groups, respectively (P < 0.001). The difference in cumulative incidence applied to both patients with Gleason score 6 (P < 0.001) and 7 (3 + 4) (P = 0.004). There was no difference in the 5-year cumulative incidence of BCR between patients with pre-ISUP Gleason score 6 and post-ISUP Gleason score 7 (3 + 4) (P = 0.34). In a multiple Cox-proportional hazard regression model, ISUP 2005 grading was a strong prognostic factor for BCR within 5 years of RP (hazard ratio 0.34; 95% confidence interval 0.22-0.54; P < 0.001).
The revision of the Gleason grading system has reduced the risk of BCR after RP in patients with biopsy Gleason score 6 and 7 (3 + 4). This may have consequences when comparing outcomes across studies and historical periods and may affect future treatment recommendations.
国际泌尿病理学会(ISUP)2005年对Gleason分级系统的修订是否影响了根治性前列腺切除术(RP)后生化复发(BCR)的风险,因为新指南意味着一些先前分级为Gleason评分6(3+3)的前列腺癌现在被视为7(3+4)。
进行配对分析。共有215例在2005年12月31日前接受RP的活检Gleason评分6或7(3+4)前列腺癌患者(ISUP前组),根据活检Gleason评分、临床肿瘤类别、PSA水平和切缘状态与2008年1月1日至2011年12月31日期间接受RP的患者1:1配对(ISUP后组)。对患者进行随访,直至BCR定义为PSA水平≥0.2 ng/mL。在竞争风险模型中分析BCR风险。
ISUP前组的中位随访时间为9.5年,ISUP后组为4.8年。ISUP前组和ISUP后组的5年BCR累积发生率分别为34.0%和13.9%(P<0.001)。累积发生率的差异适用于Gleason评分6(P<0.001)和7(3+4)(P=0.004)的患者。ISUP前Gleason评分6的患者与ISUP后Gleason评分7(3+4)的患者在5年BCR累积发生率上无差异(P=0.34)。在多因素Cox比例风险回归模型中,ISUP 2005分级是RP后5年内BCR的强预后因素(风险比0.34;95%置信区间0.22-0.54;P<0.001)。
Gleason分级系统的修订降低了活检Gleason评分6和7(3+4)患者RP后BCR的风险。这在比较不同研究和历史时期的结果时可能会产生影响,并可能影响未来的治疗建议。